329974-09-6Relevant articles and documents
HETEROARYLAMINOISOQUINOLINES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF
-
Page/Page column 109, (2016/08/23)
The application is directed to compounds of formula (IA) : and specifically compounds of formula (I) and their salts and solvates, wherein R1, R11, R12, R13, R4, R5, n, A1, A2, and A3 are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.
Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase
Hebeisen, Paul,Haap, Wolfgang,Kuhn, Bernd,Mohr, Peter,Wessel, Hans Peter,Zutter, Ulrich,Kirchner, Stephan,Ruf, Armin,Benz, J?rg,Joseph, Catherine,Alvarez-Sánchez, Rubén,Gubler, Marcel,Schott, Brigitte,Benardeau, Agnes,Tozzo, Effie,Kitas, Eric
scheme or table, p. 3237 - 3242 (2011/07/07)
A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase.
Lead generation: Sowing the seeds for future success
Bleicher, Konrad H.,Nettekoven, Matthias,Peters, Jens-Uwe,Wyler, Rene
, p. 588 - 600 (2007/10/03)
Lead generation and the associated hit-to-lead process are key strategic elements in modern pharmaceutical research, and most companies have implemented this concept. Efficient lead generation is one of the main attempts to reduce the high attrition rates observed along the drug discovery process by focussing on the early developmental phases. The level of integration of the lead generation activities within the discovery organization, the flexibility in assessing and implementing new chemistries and new technologies, the high-quality standards set for the identification of the best possible chemical lead series will ultimately determine the future success in discovering new medicines.
Model Systems for Flavoenzyme Activity: Interplay of Hydrogen Bonding and Aromatic Stacking in Cofactor Redox Modulation
Gray, Mark,Goodman, Allan J.,Carroll, Joseph B.,Bardon, Kevin,Markey, Michael,Cooke, Graeme,Rotello, Vincent M.
, p. 385 - 388 (2007/10/03)
(Equation presented) A model system has been developed to study the synergy between aromatic stacking and hydrogen bonding in the binding of a flavin derivative. The results show that the identity of both the hydrogen bonding and π-stacking units strongly determine the overall receptor affinity for flavin in both the oxidized and radical anion forms.
The development of a practical and reliable large-scale synthesis of 2,6-diamino-4-bromopyridine
Nettekoven, Matthias,Jenny, Christian
, p. 38 - 43 (2013/09/05)
A novel, safer, and efficient synthetic route to 2,6-diamino-4-bromopyridine has been developed. In discovery research a five-step synthesis afforded 2,6-diamino-4-bromopyridine in 56% yield with a double Curtius rearrangement as a key transformation. Due to potential safety concerns on larger scale an alternative synthetic strategy was necessary. Starting from 2,4-dibromopyridine-N-oxide two complementary procedures have been developed to access 2,6-diamino-4-bromopyridine. The four-step procedure yielded in 28% overall, and the five-step procedure, in 33% overall 2,6-diamino-4-bromopyridine in a safe and straightforward manner using a regioselective 2,6-diamination reaction as key step. Additionally, a general route to unsymmetrical substituted pyridine N-oxide derivatives is disclosed.
Amino-triazolopyridine derivatives
-
Page column 27-28, (2010/02/05)
The invention relates to compounds of formula wherein R1is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, —(CH2)nOH, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenyl group, or is phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy or is —O(CH2)n,phenyl, benzofuryl, indolyl or benzothiophenyl, or is —S-lower alkyl; R2and R4are independently from each other hydrogen, cyano or —S(O)2-phenyl; R3is hydrogen, halogen or is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, —(CH2)n-aryl, hydroxy, halogen, lower alkoxy, morpholinyl, amino, lower alkylamino or —C(O)NR′2, and wherein R′ is lower alkyl or hydrogen, or is phenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF3, —OCF3, —NHC(O)lower alkyl, cyano, —C(O)-lower alkyl, —C(O)O-lower alkyl, —S-lower alkyl, —S(O)2NH-phenyl, —S(O)2-methylpiperazinyl; or is —NR′R″, wherein R′ and R″ are independently from each other hydrogen, —(CH2)nphenyl, which phenyl ring is optionally substituted by halogen or lower alkoxy, —CH(lower alkyl)-phenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is —O-phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, —O-tetrahydronaphthalenyl or —O—CH2-6-methyl-pyridin-2-yl; or is -benzo[1,3]dioxolyl, -1H-indol-5-yl, naphthyl, benzofuran-2-yl, 1,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morpholinyl; R5is —NR2, wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, —CO-lower alkyl, —CO-lower alkoxy, -lower alkenyl, —CO(CH2)n-phenyl or —COO(CH2)n-phenyl, wherein the phenyl ring is optionally substituted by CF3, lower alkoxy, halogen or lower alkyl, —CO(CH2)3-NHCO-lower alkoxy, —(CH2)n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF3or halogen, or is 4,5-dihydro-1H-imidazol-2-yl-benzoic acid, 1,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl-benzoic acid; n is 0-4 and their pharmaceutically acceptable salts
Combinatorial synthesis of 5-aryl-[1,2,4]-triazolo-[1,5-a]-pyridine derivatives as potential inhibitors of the adenosine 2A receptor
Nettekoven
, p. 1917 - 1920 (2007/10/03)
A novel and efficient 4-step synthesis of 2,4-diamino-4-bromo-pyridine 4 in 56% overall yield by a double Curtius rearrangement as a key step is reported. N-amination of 2,4-diamino-4-bromo-pyridine 4 with O-mesitylenesulfonylhydroxylamine 10 and subsequent reaction with aldehydes yielded, upon oxidative ring-closure, 5-bromo-triazolopyridines 2a-2f. Thereafter, from a combinatorial parallel Suzuki cross-coupling reaction 260 previously non-described 5-aryl-[1,2,4]-triazolo-[1,5-a]-pyridines 1 were obtained in acceptable overall yield.
